Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.79 |
| ▸ | CA1 | P00915 | 1/20 | 0.79 |
| ▸ | CA2 | P00918 | 1/20 | 0.79 |
| ▸ | CA3 | P07451 | 1/20 | 0.79 |
| ▸ | CA4 | P22748 | 1/20 | 0.79 |
| ▸ | CA6 | P23280 | 1/20 | 0.79 |
| ▸ | CA5A | P35218 | 1/20 | 0.79 |
| ▸ | CA7 | P43166 | 1/20 | 0.79 |
| ▸ | CA9 | Q16790 | 1/20 | 0.79 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.79 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980310 | 0.88 | CA12 (1.00) | CA12CA1CA2CA3CA4 | |
| SCHEMBL11495843 | 0.87 | CA12 (0.77) | CA12CA1CA2CA3CA4 | |
| Hydrochloric Acid SCHEMBL11339314 | 0.87 | CA12 (0.97) | CA12CA1CA2CA3CA4 | |
| SCHEMBL28445182 | 0.87 | CA12 (0.77) | CA12CA1CA2CA3CA4 | |
| SCHEMBL11339310 | 0.87 | CA12 (0.77) | CA12CA1CA2CA3CA4 | |
| SCHEMBL2300842 | 0.84 | HSD17B10 (0.67) | CA12CA1CA2CA3CA4 | |
| SCHEMBL2034208 | 0.83 | CA12 (0.76) | CA12CA1CA2CA3CA4 | |
| SCHEMBL31619161 | 0.83 | CA12 (0.71) | CA12CA1CA2CA3CA4 | |
| SCHEMBL981812 | 0.83 | MAPT (0.78) | CA12CA1CA2CA3CA4 | |
| SCHEMBL28708408 | 0.83 | CA12 (0.67) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115340532-B | Wide-band optical absorption molecular material and application thereof | 广东省科学院测试分析研究所(中国广州分析测试中心) | 2024-04-23 | — | — | CN | disclosed |
| CN-115340532-A | Broadband optical absorption molecular material and application thereof | 广东省科学院测试分析研究所(中国广州分析测试中心) | 2022-11-15 | — | — | CN | disclosed |
| CN-105524034-B | Preparation, pharmacological action and the application for treating cerebral ischemia of coumarin derivative | 北京大学 | 2018-08-17 | — | — | CN | disclosed |
| CN-105566269-B | Preparation, pharmacological action and the application for treating itch of coumarin derivative | 北京大学 | 2018-07-10 | — | — | CN | disclosed |
| CN-105566269-A | Preparation and pharmacological effects of coumarin derivative and application of coumarin derivative to treatment on pruritus | UNIV BEIJING | 2016-05-11 | — | — | CN | disclosed |
| CN-105524034-A | Preparation method of coumarin derivative, pharmacological effect of coumarin derivative and use of coumarin derivative in treatment on cerebral ischemia | UNIV BEIJING | 2016-04-27 | — | — | CN | disclosed |
| US-7939554-B2 | Of Src homology protein tyrosine phosphatase 1; phenyl isothiazolones or a benzo-1,4-quinone; antineoplastic agents; immunostimulants inducing a cytokine response; side effect reduction | THE CLEVELAND CLINIC FOUNDATION (US) | 2011-05-10 | — | — | US | disclosed |
| US-20080103160-A1 | Protein phosphatase inhibitors | THE CLEVELAND CLINIC FOUNDATION | 2008-05-01 | — | — | US | disclosed |
| US-20080051464-A1 | Protein phosphatase inhibitors | THE CLEVELAND CLINIC FOUNDATION | 2008-02-28 | — | — | US | disclosed |
| EP-0889361-B1 | Initiators for cationic polymerization | SIEMENS AG (DE) | 2002-01-23 | — | — | EP | disclosed |
| US-6162881-A | Initiators for cationic polymerization | SIEMENS AKTIEGESELLSCHAFT (DE) | 2000-12-19 | — | — | US | disclosed |
| EP-0889361-A1 | Initiators for cationic polymerization | SIEMENS AKTIENGESELLSCHAFT (DE) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103160-A1 | Protein phosphatase inhibitors | PPM1A, DUSP15, PPM1B | CA12 4744/4885CA1 3794/4885CA2 2926/4885 |
| US-20080051464-A1 | Protein phosphatase inhibitors | PPM1A, DUSP15, PPM1B | CA12 4744/4885CA1 3794/4885CA2 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.